Collaboration combines Arkstone’s cutting-edge AI technology and infectious disease expertise with Dendi’s innovative LIS
Dendi, a leading software provider for high-complexity diagnostic laboratories, has developed a lab informatics platform that challenges and extends the traditional concept of a LIS. With its full-fledged interoperability capabilities, it acts as a “complete operating system for labs”, allowing them to efficiently integrate with any system to help labs expand their offerings.
Arkstone provides clinical decision support (CDS) software for healthcare providers, most notably the OneChoice Report. Its tight integration with Dendi LIS provides healthcare providers with access to a powerful solution that breaks down complex molecular diagnostic results into clear, easy-to-understand interpretations and evidence-based recommendations. This technology streamlines workflows and ultimately helps physicians make informed decisions when choosing a treatment regimen.
“We are thrilled to partner with Dendi and offer laboratories a turnkey solution that not only streamlines workflows but also provides actionable results in accordance with antimicrobial stewardship, and standard of care clinical practice guidelines,” said Dr. Frenkel, M.D. Arkstone co-founder, Chief Science Officer, and Infectious Disease Specialist.
The timing of this partnership couldn’t be better. With lower reimbursement rates, staffing issues, and growing competition, healthcare providers (including diagnostic laboratories) are facing increasingly tough market conditions. By offering a user-friendly clinical decision support technology, laboratories now have a key differentiator that will help them stand out from the competition while also providing actionable and usable information.
“For diagnostic labs, adding clinical decision support tools should be a no-brainer and the de facto standard for molecular diagnostic testing. Partnering with an industry-leading partner like Arkstone to create a tightly-integrated solution eliminates implementation timelines and makes the ROI that much more self-evident,” said Jihoon Baek, Cofounder & Chief Executive Officer of Dendi.
Overall, this partnership between Arkstone Medical Solutions and Dendi represents a significant step forward in providing healthcare providers with the tools and technologies they need to make informed clinical decisions. With their combined expertise and innovative technology solutions, these companies are poised to make a real difference in the healthcare industry and beyond.
Arkstone is committed to stem the global spread of antimicrobial resistance and the misuse of antibiotics by marrying advanced artificial intelligence with a deep understanding of infectious disease. Arkstone’s patent-pending OneChoice technology helps physicians practice precision-guided medicine through optimal treatment regimen recommendations. Additionally, the proprietary ArkScore system allows providers to compare antibiotics at a glance through an easy to understand visual score. Learn more at www.arkstonemedical.com or email email@example.com